Neurology
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Sanofi’s oral TREM2 agonist SAR448851 is moving toward Phase II testing in early Alzheimer’s disease. The mechanism is compelling. The field has already learned that TREM2 biology can disappoint.
Huntington’s Needs More Than a Better Curve
Duchenne’s Accelerated Approval Faces Its Test
Neurology Is Trying to Stop Nerves Dying, Not Just Treat What Is Left
MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.
MS Does Not End at the Clinic Door. It Follows People Into Work, Money and Relationships.
For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door
A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.
When the Test Says Normal but the Pain Does Not
When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.